# AI in Healthcare: How Artificial Intelligence Is Changing Medical Diagnosis > Source: > Published: 2026-10-07 18:07:41+00:00 Originally published on [The Daily Flare](https://thedailyflare.com). AI in healthcare is no longer experimental. Across radiology, cardiology, and neurology, artificial intelligence now helps doctors detect disease earlier and work faster — but not every tool lives up to the hype. The scale of the change is easiest to see in the FDA's numbers. The agency keeps a public list of authorized AI-enabled medical devices, which reached roughly 1,451 entries at the end of 2025, with about 300 added that year alone. One nuance matters: nearly 97 percent of these devices reached the market through the 510(k) pathway, which clears a product by showing it is substantially equivalent to an existing device rather than by proving it improves patient outcomes. Mammography screening offers the strongest population-level evidence. The Swedish MASAI trial, a randomized controlled trial of more than 105,000 women in the national screening program published in The Lancet Digital Health, compared AI-supported screening against standard double reading. Cancer detection rose 29 percent with no increase in false positives, and radiologists' screen-reading workload fell 44 percent. Honesty requires the counterpoint: a Johns Hopkins study published in March 2026 found that the same AI tool showed no significant change in cancer detection or recall in a real-world US setting — European results come from double-reading systems, where AI replaces one human reader; US practice uses single reading, which may behave differently. Lung cancer screening is the next frontier. In February 2026 the FDA cleared Median Technologies' Eyonis LCS, the first product to combine detection and diagnostic assistance for lung nodules on low-dose CT in a single tool. Its REALITY validation study reported a patient-level AUC of 0.904, with 80.1 percent sensitivity and 86.6 percent specificity. Stroke triage shows what speed gains look like: Viz.ai's large-vessel-occlusion platform was FDA-cleared in February 2018, reaching 90 percent sensitivity and specificity with a median scan-to-notification time under six minutes. Pathology is real but much younger: Paige Prostate, granted De Novo authorization in September 2021, was the first FDA-authorized AI application in pathology. Overall, radiology accounts for 76.5 percent of AI authorization records — AI in medical diagnosis has, so far, been overwhelmingly about interpreting images. | Area | What AI does | Status | |---|---|---| | Breast screening | Flags suspicious areas on mammograms | FDA-cleared; strongest trial evidence (MASAI) | | Lung screening | Detects and risk-scores nodules on low-dose CT | FDA-cleared 2026; large-trial support | | Stroke triage | Alerts specialists to large-vessel occlusions | FDA-cleared since 2018; ER adoption growing | | Diabetic eye screening | Issues a screening result with no specialist reading the images | First autonomous AI, cleared 2018 | | Pathology | Assists pathologists on biopsy slides | First clearance 2021; still a young field | | Sepsis prediction | Warns of sepsis risk from health records | Widely deployed; weak validation — treat with caution | | Clinical documentation | Drafts notes from patient visits | In use; RCTs show time and burnout gains | | Diagnostic chatbots | Suggests diagnoses from symptoms and case data | Investigational; not ready for unsupervised clinical use | The autonomous milestone deserves special attention: Luminetics (formerly IDx-DR), authorized through the FDA's De Novo pathway in April 2018, delivers a screening decision for diabetic retinopathy with no clinician interpreting the retinal images — and it can be used in primary care. The pivotal trial of 900 patients reported 87.4 percent sensitivity and 89.5 percent specificity. That matters because roughly half of US patients with diabetes skip their annual eye exam. But "AI is everywhere" does not mean "AI works everywhere." The cautionary tale is sepsis prediction. Epic's widely deployed sepsis model — used at hundreds of US hospitals — is not FDA-authorized, and independent external validation told a different story: an AUC of 0.63 versus the claimed 0.76–0.83, and the model catching sepsis in only 7 percent of cases clinicians had missed. Neurology offers a middle ground where AI assistance is gaining ground in triage and imaging while research into slower-developing brain disease continues, though clinical AI tools there remain early. The through line is the same: AI in healthcare is genuinely changing medical diagnosis — but the tools that change it safely are the ones tested in real workflows, monitored after deployment, and kept under human oversight. Cleared is not the same as proven.